E David Crawford1, Daniel P Petrylak2, Neal Shore3, Fred Saad4, Susan F Slovin5, Nicholas J Vogelzang6, Thomas E Keane7, Phillip J Koo8, Leonard G Gomella9, Joe M O'Sullivan10, Bertrand Tombal11, Raoul S Concepcion12, Paul Sieber13, Nelson N Stone14, Steven E Finkelstein15, Evan Y Yu16. 1. University of Colorado, Denver, CO. Electronic address: edc@edavidcrawford.com. 2. Yale University, New Haven, CT. 3. Carolina Urologic Research Center, Myrtle Beach, SC. 4. Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada. 5. Memorial Sloan Kettering Cancer Center, New York, NY. 6. Comprehensive Cancer Centers of Nevada, Las Vegas, NV. 7. Medical University of South Carolina, Charleston, SC. 8. Banner MD Anderson Cancer Center, Gilbert, AZ. 9. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA. 10. Queen's University Belfast, Belfast, Northern Ireland, UK. 11. Université Catholique de Louvain, Brussels, Belgium. 12. Comprehensive Prostate Center, Nashville, TN. 13. Lancaster Urology, Lancaster, PA. 14. Icahn School of Medicine at Mount Sinai, New York, NY. 15. NRG Immunotherapy and Immunomodulation Committee, Scottsdale, AZ. 16. University of Washington, Seattle, WA.
Abstract
OBJECTIVE: To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments. MATERIALS AND METHODS: The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience. RESULTS: A consensus was developed to address important questions on management of patients with metastatic CRPC. CONCLUSION: In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
OBJECTIVE: To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments. MATERIALS AND METHODS: The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience. RESULTS: A consensus was developed to address important questions on management of patients with metastatic CRPC. CONCLUSION: In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
Authors: Thorsten D Poeppel; Daria Handkiewicz-Junak; Michael Andreeff; Alexander Becherer; Andreas Bockisch; Eva Fricke; Lilli Geworski; Alexander Heinzel; Bernd J Krause; Thomas Krause; Markus Mitterhauser; Wilfried Sonnenschein; Lisa Bodei; Roberto C Delgado-Bolton; Michael Gabriel Journal: Eur J Nucl Med Mol Imaging Date: 2017-12-12 Impact factor: 9.236
Authors: Celestia S Higano; Andrew J Armstrong; A Oliver Sartor; Nicholas J Vogelzang; Philip W Kantoff; David G McLeod; Christopher M Pieczonka; David F Penson; Neal D Shore; Jeffrey Vacirca; Raoul S Concepcion; Ronald F Tutrone; Luke T Nordquist; David I Quinn; Vahan Kassabian; Mark C Scholz; Matt Harmon; Robert C Tyler; Nancy N Chang; Hong Tang; Matthew R Cooperberg Journal: Cancer Date: 2019-09-04 Impact factor: 6.860
Authors: Juan Pablo Sade; Carlos Alberto Vargas Báez; Martin Greco; Carlos Humberto Martínez; Miguel Ángel Álvarez Avitia; Carlos Palazzo; Narciso Hernández Toriz; Patricia Isabel Bernal Trujillo; Diogo Assed Bastos; Fabio Augusto Schutz; Santiago Bella; Lucas Nogueira; Neal D Shore Journal: Med Oncol Date: 2018-03-19 Impact factor: 3.064